e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Biomarkers for lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis
M. Petrovic, N. Ilic, I. Cekerevac, L. Novkovic, V. Radulovic, V. Cupurdija (Kragujevac, Republic Of Serbia)
Source:
Annual Congress 2010 - Biomarkers for lung cancer
Session:
Biomarkers for lung cancer
Session type:
Thematic Poster Session
Number:
3246
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Petrovic, N. Ilic, I. Cekerevac, L. Novkovic, V. Radulovic, V. Cupurdija (Kragujevac, Republic Of Serbia). Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis. Eur Respir J 2010; 36: Suppl. 54, 3246
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
N3 hilar sampling decision in the staging of mediastinal lung cancer
Related content which might interest you:
Prognostic value of il-6 and TNF-alfa serum concentration in advanced non-small lung cancer patients
Source: Eur Respir J 2003; 22: Suppl. 45, 251s
Year: 2003
Serum levels of interleukin 8 and plasma levels of osteopontin in patients with non-small cell lung cancer during chemotherapy
Source: Annual Congress 2011 - Instructive clinical aspects of lung cancer
Year: 2011
Plasma leptin levels in nonsmall cell lung carcinoma (NSCLC) patients at the time of the diagnosis
Source: Eur Respir J 2001; 18: Suppl. 33, 65s
Year: 2001
Serum level of interleukin-6 as a prognostic factor in advanced nonsmall-cell lung cancer
Source: Eur Respir J 2003; 22: Suppl. 45, 250s
Year: 2003
Evaluate soluble PD-L1 in plasma in advanced stage non-small cell lung cancer patients
Source: Virtual Congress 2020 – Biological mechanisms of lung cancer
Year: 2020
Serum C-reactive protein and procalcitonin levels in non-small cell lung cancer patients
Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology
Year: 2012
Serum level of GFBP-1 and IGFBP-6 in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Annual Congress 2009 - Biological and clinical markers in lung cancer
Year: 2009
Increased serum levels of IL-18 are associated with lower survival and bone metastasis in non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
C-reactive protein and assessment of chemotherapy response in advanced non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Elevated level of circulating matrix metalloproteinase-9 in non-small lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 229s
Year: 2002
Serum level of IGF-I and IGF-II in patients with non-small cell lung cancer (NSCLC) during chemotherapy
Source: Eur Respir J 2004; 24: Suppl. 48, 82s
Year: 2004
Importance of clusterin expression at tissue level for the prognosis of non-small cells lung cancer
Source: Annual Congress 2009 - Lung cancer biology
Year: 2009
Serum hepcidin and iron are associated with non-small cell lung cancer stage
Source: International Congress 2016 – Prognostic variables in lung cancer I
Year: 2016
Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer
Source: Eur Respir J 2010; 36: 885-892
Year: 2010
Association between C-reactive protein and survival in non-small cell lung cancer
Source: International Congress 2017 – Lung cancer - clinical research: scientific pearls from the bedside
Year: 2017
Serum tumor markers in lung cancer patients
Source: Annual Congress 2007 - Biology, diagnosis and rare tumours in thoracic malignancies
Year: 2007
Evaluation of serum tumour markers in the lung cancer patients
Source: Eur Respir J 2002; 20: Suppl. 38, 268s
Year: 2002
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013
Prognostic value of neutrophil to lymphocyte ratio in patients with advanced non-small cell lung cancer
Source: Virtual Congress 2021 – Therapy of lung cancer
Year: 2021
Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer (NSCLC) treated with nivolumab (nivo).
Source: International Congress 2018 – Lung cancer: new aspects in diagnosis and management
Year: 2018
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept